IGMS IGM Biosciences, Inc.

Nasdaq igmbio.com


$ 1.28 $ -0.03 (-2.31 %)    

Wednesday, 13-Aug-2025 16:45:38 EDT
QQQ $ 601.99 $ 12.51 (2.12 %)
DIA $ 460.94 $ 5.81 (1.28 %)
SPY $ 663.01 $ 10.02 (1.53 %)
TLT $ 90.51 $ -0.05 (-0.06 %)
GLD $ 378.45 $ 8.97 (2.43 %)
$ 1.27
$ 1.30
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 0.92 - $ 22.50
1,618,937
na
76.57M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-hold-on-igm-biosciences-lowers-price-target-to-1

Truist Securities analyst Asthika Goonewardene maintains IGM Biosciences (NASDAQ:IGMS) with a Hold and lowers the price targ...

 igm-biosciences-q1-eps-050-misses-048-estimate-sales-49900k-miss-310m-estimate

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0...

 jp-morgan-upgrades-igm-biosciences-to-neutral

JP Morgan analyst Eric Joseph upgrades IGM Biosciences (NASDAQ:IGMS) from Underweight to Neutral.

 jefferies-downgrades-igm-biosciences-to-hold-lowers-price-target-to-2

Jefferies analyst Roger Song downgrades IGM Biosciences (NASDAQ:IGMS) from Buy to Hold and lowers the price target from $48 ...

 truist-securities-maintains-hold-on-igm-biosciences-lowers-price-target-to-2

Truist Securities analyst Asthika Goonewardene maintains IGM Biosciences (NASDAQ:IGMS) with a Hold and lowers the price targ...

 stifel-downgrades-igm-biosciences-to-hold-lowers-price-target-to-25

Stifel analyst Stephen Willey downgrades IGM Biosciences (NASDAQ:IGMS) from Buy to Hold and lowers the price target from $27...

 rbc-capital-downgrades-igm-biosciences-to-sector-perform-lowers-price-target-to-15

RBC Capital analyst Brian Abrahams downgrades IGM Biosciences (NASDAQ:IGMS) from Outperform to Sector Perform and lowers the...

 us-stocks-to-open-on-a-tentative-note-as-traders-remain-cautious-ahead-of-fridays-crucial-jobs-data

U.S. stock futures were on a mixed note on Friday ahead of the crucial U.S. jobs data report after a mixed close in the previou...

 bmo-capital-downgrades-igm-biosciences-to-market-perform-lowers-price-target-to-2

BMO Capital analyst Etzer Darout downgrades IGM Biosciences (NASDAQ:IGMS) from Outperform to Market Perform and lowers the p...

 igm-biosciences-halts-further-development-of-imvotamab-and-igm-2644-plans-reducing-its-workforce-by-73

"Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the...

 bmo-capital-initiates-coverage-on-igm-biosciences-with-outperform-rating-announces-price-target-of-21

BMO Capital analyst Etzer Darout initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Outperform rating and announces ...

 stifel-maintains-buy-on-igm-biosciences-raises-price-target-to-27

Stifel analyst Stephen Willey maintains IGM Biosciences (NASDAQ:IGMS) with a Buy and raises the price target from $25 to $27.

 igm-biosciences-q3-2024-gaap-eps-101-misses-080-estimate-sales-516000k-beat-267222k-estimate

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION